Investment to Date
Since 2013
-
- USD
M - Total Investment
- USD
-
- Total Invested
Partnerships
-
- Total Product
Development Partners
-
- Clinical Trials
Breakdown

(USD 1.00 = JPY 100)
- Malaria $5,356,668,398 (40.6%)
- Tuberculosis $5,356,668,398 (40.6%)
- NTDs $5,356,668,398 (40.6%)

(USD 1.00 = JPY 100)
- Drugs $5,356,668,398 (40.6%)
- Vaccines $5,356,668,398 (40.6%)
- Diagnostics $5,356,668,398 (40.6%)
Stage

(USD 1.00 = JPY 100)
- Discovery $5,356,668,398 (40.6%)
- Preclinical $5,356,668,398 (40.6%)
- Clinical $5,356,668,398 (40.6%)
GHIT invests using Japanese yen. US dollar amounts represent conversions from Japanese yen, solely for the reader’s convenience, at JPY 100 = USD 1.
Every project is counted as a single investment, even if it has received multiple rounds of GHIT funding.
Due to rounding, total percentages under each category may not add up precisely to 100.
For projects that span across multiple GHIT investment platforms (i.e., programs that transition from one platform to the other), the total investment amount is shown based on the project's most current development status.
Find an Investment
Each awarded project is listed once, regardless of whether it has received multiple investments from GHIT.
Development stage categories are as follows:
Drugs and Vaccines
Discovery: From Target Research to Hit-to-Lead | Preclinical: Preclinical Development| Clinical: From Phase I to Registration
Diagnostics
Discovery: Target Research|Preclinical: Product Design|Clinical: From Product Development to Registration
Development Stage | Current Stage | Disease | Intervention | RFP Year | Status | Project | Partner | Awarded Amount | Details |
---|---|---|---|---|---|---|---|---|---|
Discovery | Drug Hit Identification | Malaria | Drug | 2013 | COMPLETE | Screening Program | Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) | $104,264 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2013 | COMPLETE | Screening Program | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) | $73,940 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2013 | COMPLETE | Screening Program | Kitasato Institute,Medicines for Malaria Venture (MMV) | $570 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2013 | TERMINATED | Screening Program | Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV) | $241,372 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2013 | TERMINATED | Screening Program | Institute of Microbial Chemistry,Medicines for Malaria Venture (MMV) | $11,286 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2014 | COMPLETE | Screening Program | Mitsubishi Tanabe Pharma Corporation,Medicines for Malaria Venture (MMV) | $186,420 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2014 | COMPLETE | Screening Program | Sumitomo Dainippon Pharma Co., Ltd.,Medicines for Malaria Venture (MMV) | $137,883 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2014 | COMPLETE | Design and Cost-effective de novo Synthesis of Aza-artemisinins | Kitasato Institute,Medicines for Malaria Venture (MMV),Hokkaido University | $60,000 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2014 | TERMINATED | Identification of lead compounds for anti-Malarial agent | Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV) | $636,941 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2015 | COMPLETE | Hit-to-Lead Discovery for New Anti-malarials in Collaboration between MMV and Eisai | Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) | $779,760 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2015 | COMPLETE | Antimalarial hits from whole cell screening | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) | $764,033 | Details |
Discovery | Drug Target Validation | Malaria | Drug | 2015 | COMPLETE | Proteasome inhibitors as new potent resistance-reversing antimalarials | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV),The University of Melbourne | $297,133 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2015 | COMPLETE | Screening Program | Daiichi Sankyo RD Novare Co., Ltd.,Medicines for Malaria Venture (MMV) | $150,000 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2015 | COMPLETE | Screening Program | Op Bio Factory Co., Ltd.,Medicines for Malaria Venture (MMV) | $68,400 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2016 | COMPLETE | New Hit-to-Lead Activity for New Anti-Malarias between MMV and Eisai | Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) | $750,000 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2016 | COMPLETE | Mitsubishi Tanabe malaria Hit-to-Lead | Mitsubishi Tanabe Pharma Corporation,Medicines for Malaria Venture (MMV) | $618,222 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2016 | COMPLETE | New Hit-to-Lead Activity for New Anti-Malarias between MMV and Takeda | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) | $483,360 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2017 | COMPLETE | HTL for selective Plasmodium proteasome inhibitors as new potent resistance-reversing antimalarials | Takeda Pharmaceutical Company Limited,The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute,Medicines for Malaria Venture (MMV) | $461,245 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2017 | COMPLETE | New Hit-to-Lead Activity for New Anti-Malaria drugs between MMV and Sumitomo Dainippon Pharma | Sumitomo Dainippon Pharma Co., Ltd.,Medicines for Malaria Venture (MMV) | $445,500 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2017 | COMPLETE | Screening Program | Astellas Pharma Inc.,Medicines for Malaria Venture (MMV) | $65,836 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2017 | COMPLETE | Screening Program | Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) | $49,500 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2018 | COMPLETE | New Hit-to-Lead Activity for New Anti-Malarials between MMV and Takeda | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) | $528,000 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2018 | COMPLETE | Screening Program | University of Tokyo,Medicines for Malaria Venture (MMV) | $150,000 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2019 | COMPLETE | Development of nucleoside sulfamates as novel antimalarials | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV),The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute | $1,016,129 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2019 | COMPLETE | Proteasome inhibitors as new potent antimalarials | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV),The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute | $526,140 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2019 | COMPLETE | Screening project between Takeda and MMV | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) | $41,962 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2020 | ACTIVE | Hit-to-lead development of new antimalarial compounds from DDI library | University of Tokyo,Medicines for Malaria Venture (MMV) | $1,167,442 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2020 | ACTIVE | Pioneering antisense oligonucleotides as long-acting malaria prophylactics | Eisai Co., Ltd.,University of California, San Diego (UCSD) | $922,972 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2020 | ACTIVE | Screening Program | Daiichi Sankyo, Inc.,Eisai Co., Ltd.,Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) | $210,936 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2020 | COMPLETE | Prolyl tRNA Synthetase Inhibitors for New Antimalarials | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) | $547,268 | Details |
Discovery | Drug Hit Identification | Malaria | Drug | 2020 | COMPLETE | Screening Program | Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV) | $122,013 | Details |
Discovery | Drug Lead Identification | Malaria | Drug | 2021 | ACTIVE | Hit-to-Lead development of novel Astellas compounds with antimalarial activity | Astellas Pharma Inc.,Medicines for Malaria Venture (MMV),TCG Lifesciences Private Limited. (TCGLS) | $1,317,435 | Details |
Discovery | Drug Target Identification | Malaria | Drug | 2021 | ACTIVE | Identification and Validation of potential Plasmodium E3 Ligases for PROTAC Platform | FIMECS, Inc.,National Center for Genetic Engineering and Biotechnology (BIOTEC) | $838,587 | Details |
Discovery | Vaccine Technology Platform Identification | Malaria | Vaccine | 2013 | COMPLETE | Accelerating Development of Vaccines for Malaria Elimination Using a Novel Clinical Target Validation Approach | CellFree Sciences Co. Ltd.,Ehime University,PATH Malaria Vaccine Initiative | $591,396 | Details |
Discovery | Vaccine Technology Platform Identification | Malaria | Vaccine | 2014 | COMPLETE | Accelerating Development of Transmission-Blocking Vaccines for Malaria Elimination Using a Novel Vaccine Candidate | Ehime University,PATH Malaria Vaccine Initiative | $766,098 | Details |
Discovery | Vaccine Antigen Identification | Malaria | Vaccine | 2016 | COMPLETE | A Vaccine to Block Malaria Transmission: Pfs230 Antigen Design and Display | Ehime University,PATH Malaria Vaccine Initiative | $595,650 | Details |
Discovery | Vaccine Antigen Identification | Malaria | Vaccine | 2017 | COMPLETE | Identification of Vaccine Targets that Will Block the Interaction of Plasmodium falciparum Malaria Parasites with a Complement Regulator | Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Antigen Discovery, Inc.,The Pennsylvania State University | $881,900 | Details |
Discovery | Vaccine Vaccine Concept Development | Malaria | Vaccine | 2019 | ACTIVE | Made-in-Japan next-generation vaccine platform effective for multistage Plasmodium for infants | Hokkaido University,Jichi Medical University,Toyama University,University of Cambridge,Kanazawa University | $526,900 | Details |
Discovery | Vaccine Antigen Identification | Malaria | Vaccine | 2019 | COMPLETE | Co-delivery of Pfs230C1 and CSP with CoPoP, a versatile, potent liposomal adjuvant system for multistage malaria vaccine | Ehime University,University at Buffalo, The State University of New York,PATH Malaria Vaccine Initiative | $972,951 | Details |
Discovery | Vaccine Technology Platform Identification | Malaria | Vaccine | 2019 | COMPLETE | Development of a novel Pvs25 nucleoside-modified mRNA vaccine that induces potent and long-lasting transmission blocking immunity | Tokyo Medical and Dental University,University of Pennsylvania,Mahidol University | $960,771 | Details |
Discovery | Vaccine Antigen Identification | Malaria | Vaccine | 2020 | ACTIVE | Evaluation of a malaria vaccine candidate comprised of full-length recombinant CSP formulated with SA-1 adjuvant, using RTS,S/AS01 as a benchmark | Ehime University,Sumitomo Dainippon Pharma Co., Ltd.,PATH | $999,733 | Details |
Discovery | Vaccine Antigen Identification | Malaria | Vaccine | 2021 | ACTIVE | Development of a Plasmodium vivax multistage vaccine effective both for protection and transmission blocking | Hokkaido University,Instituto Leônidas & Maria Deane (ILMD) and The Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD),Jichi Medical University,Kyoto University,Toyama University,University of Cambridge,Kanazawa University | $698,170 | Details |
Discovery | Diagnostic Technical Feasibility | Malaria | Diagnostic | 2015 | COMPLETE | Development of serological biomarkers as indicators of recent and asymptomatic infections for innovative tools to accelerate malaria elimination | CellFree Sciences Co. Ltd.,Foundation for Innovative New Diagnostics (FIND),Proteo-Science Centre, Ehime University,The Walter and Eliza Hall Institute of Medical Research | $993,030 | Details |
Discovery | Diagnostic Concept Development | Malaria | Diagnostic | 2017 | COMPLETE | Towards rapid diagnosis of Plasmodium vivax malaria hypnozoite infection | National Institute of Technology, Kumamoto College,Biomedical Primate Research Centre,Institute of Tropical Medicine (NEKKEN) Nagasaki University | $728,830 | Details |
Discovery | Diagnostic Technical Feasibility | Malaria | Diagnostic | 2020 | ACTIVE | Towards the rapid diagnosis of malaria hypnozoite infection: feasibility studies | National Institute of Technology, Kumamoto College,Biomedical Primate Research Centre,Institute of Tropical Medicine (NEKKEN) Nagasaki University | $999,809 | Details |
Discovery | Drug Hit Identification | Tuberculosis | Drug | 2013 | COMPLETE | Screening Program | SHIONOGI & CO., LTD.,The Global Alliance for TB Drug Development | $105,450 | Details |
Discovery | Drug Hit Identification | Tuberculosis | Drug | 2013 | COMPLETE | Screening Program | Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development | $55,550 | Details |
Discovery | Drug Hit Identification | Tuberculosis | Drug | 2013 | TERMINATED | Screening Program | Daiichi Sankyo, Inc.,The Global Alliance for TB Drug Development | $135,300 | Details |
Discovery | Drug Hit Identification | Tuberculosis | Drug | 2014 | COMPLETE | Screening Program | Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development | $150,000 | Details |
Discovery | Drug Hit Identification | Tuberculosis | Drug | 2014 | TERMINATED | Screening Program | Op Bio Factory Co., Ltd.,The Global Alliance for TB Drug Development | $150,000 | Details |
Discovery | Drug Lead Identification | Tuberculosis | Drug | 2015 | COMPLETE | Hit-to-Lead Development of anti-TB Phenotypic Screening Hits | The Research Institute of Tuberculosis, Japan Anti-tuberculosis Association,The Global Alliance for TB Drug Development,SHIONOGI & CO., LTD. | $999,720 | Details |
Discovery | Drug Lead Identification | Tuberculosis | Drug | 2015 | COMPLETE | Development of Phenotypic Screening Hits against Mycobacterium tuberculosis | Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development | $792,165 | Details |
Discovery | Drug Hit Identification | Tuberculosis | Drug | 2015 | COMPLETE | Screening Program | Toyama Prefectural University,The Global Alliance for TB Drug Development,HYPHAGENESIS INC. | $150,000 | Details |
Discovery | Drug Hit Identification | Tuberculosis | Drug | 2015 | COMPLETE | Screening Program | Chugai Pharmaceutical Co., Ltd.,The Global Alliance for TB Drug Development | $150,000 | Details |
Discovery | Drug Hit Identification | Tuberculosis | Drug | 2015 | COMPLETE | Screening Program | Mitsubishi Tanabe Pharma Corporation,The Global Alliance for TB Drug Development | $132,000 | Details |
Discovery | Drug Hit Identification | Tuberculosis | Drug | 2015 | COMPLETE | Screening Program | Sumitomo Dainippon Pharma Co., Ltd.,The Global Alliance for TB Drug Development | $79,200 | Details |
Discovery | Drug Lead Identification | Tuberculosis | Drug | 2015 | TERMINATED | Identification of lead compounds as novel anti‐TB agents | Daiichi Sankyo, Inc.,The Global Alliance for TB Drug Development | $908,231 | Details |
Discovery | Drug Target Validation | Tuberculosis | Drug | 2016 | COMPLETE | Host-directed drug targeting against tuberculosis | RIKEN,International Centre for Genetic Engineering and Biotechnology | $204,990 | Details |
Discovery | Drug Hit Identification | Tuberculosis | Drug | 2017 | COMPLETE | Screening Program | Astellas Pharma Inc.,The Global Alliance for TB Drug Development | $99,986 | Details |
Discovery | Drug Lead Identification | Tuberculosis | Drug | 2018 | ACTIVE | Hit-to-Lead Development of Novel anti-TB Natural Products | Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development | $1,192,440 | Details |
Discovery | Drug Hit Identification | Tuberculosis | Drug | 2018 | TERMINATED | Screening Program | Fujifilm Corporation ,The Global Alliance for TB Drug Development | $110,000 | Details |
Discovery | Drug Lead Identification | Tuberculosis | Drug | 2019 | ACTIVE | Hit-to-Lead Development of Phenotypic and Mechanism-based Screen Hits | Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development | $1,112,058 | Details |
Discovery | Drug Lead Identification | Tuberculosis | Drug | 2019 | ACTIVE | Hit-to-Lead Development of Phenotypic Screening Hits | Chugai Pharmaceutical Co., Ltd.,The Global Alliance for TB Drug Development | $953,159 | Details |
Discovery | Drug Target Identification | Tuberculosis | Drug | 2020 | ACTIVE | Identification of novel dual-acting bactericidal drug targets against Mycobacterium tuberculosis | Hokkaido University,Harvard University,Nagoya University,Research Institute of Tuberculosis ,University of Minnesota ,Fujita Health University | $974,619 | Details |
Discovery | Drug Lead Identification | Tuberculosis | Drug | 2020 | ACTIVE | Hit-to-Lead Development of Hits Identified in the Phenotypic Screening against Mycobacterium tuberculosis (Mtb) | Astellas Pharma Inc.,The Global Alliance for TB Drug Development | $801,363 | Details |
Discovery | Drug Hit Identification | Tuberculosis | Drug | 2020 | COMPLETE | Screening Program | Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development | $118,300 | Details |
Discovery | Vaccine Vaccine Concept Development | Tuberculosis | Vaccine | 2016 | COMPLETE | Development of a new mucosal vaccine for Tuberculosis using antibody engineering | University of Tokyo,Universidad de Concepcion,Instituto de Nutricion “Salvador Zubiran”,Universiti Sains Malaysia | $373,561 | Details |
Discovery | Diagnostic Concept Development | Tuberculosis | Diagnostic | 2018 | COMPLETE | Development of LFA platform for improving sensitivity of Point-of-Care assays for infectious disease with main focus on Tuberculosis and Malaria. | Asahi Kasei Corporation,Biopromic AB | $1,000,000 | Details |
Discovery | Drug Lead Identification | NTD (Chagas disease) | Drug | 2013 | COMPLETE | Optimization of Diversity-Oriented Synthesis (DOS)-derived trypanocidal small molecule ML341 towards investigational new drug status for Chagas disease | Eisai Co., Ltd.,Broad Institute | $500,000 | Details |
Discovery | Drug Hit Identification | NTD (Chagas disease / Leishmaniasis) | Drug | 2013 | COMPLETE | Screening Program | Eisai Co., Ltd.,Drugs for Neglected Diseases initiative | $75,582 | Details |
Discovery | Drug Hit Identification | NTD (Chagas disease / Leishmaniasis) | Drug | 2013 | COMPLETE | Screening Program | Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative | $75,582 | Details |
Discovery | Drug Hit Identification | NTD (Chagas disease / Leishmaniasis) | Drug | 2013 | COMPLETE | Screening Program | Kitasato Institute,Drugs for Neglected Diseases initiative | $0 | Details |
Discovery | Drug Hit Identification | NTD (Chagas disease / Leishmaniasis) | Drug | 2013 | TERMINATED | Screening Program | Institute of Microbial Chemistry,Drugs for Neglected Diseases initiative | $7,558 | Details |
Discovery | Drug Lead Identification | NTD (Chagas disease / Leishmaniasis) | Drug | 2014 | COMPLETE | Neglected Tropical Diseases Drug Discovery Booster | Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative | $795,437 | Details |
Discovery | Drug Hit Identification | NTD (Chagas disease) | Drug | 2015 | COMPLETE | Screening Program | Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative | $210,050 | Details |
Discovery | Drug Hit Identification | NTD (Leishmaniasis) | Drug | 2015 | TERMINATED | Screening Program | Eisai Co., Ltd.,Drugs for Neglected Diseases initiative | $31,000 | Details |
Discovery | Drug Target Validation | NTD (Chagas disease / Leishmaniasis) | Drug | 2016 | COMPLETE | Targeting bromodomains for novel anti-parasitic mechanisms of action for malaria, Chagas disease, leishmaniasis and cryptosporidiosis | RIKEN,McGill University ,Medicines for Malaria Venture (MMV),Structural Genomics Consortium at University of Toronto,The University of Melbourne,Drugs for Neglected Diseases initiative | $982,436 | Details |
Discovery | Drug Lead Identification | NTD (Chagas disease) | Drug | 2016 | COMPLETE | Identification of lead compounds for Leishmania donovani and/or Trypanosoma cruzi | Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative | $780,000 | Details |
Discovery | Drug Lead Identification | NTD (Chagas disease / Leishmaniasis) | Drug | 2016 | COMPLETE | Neglected Tropical Diseases Drug Discovery Booster II | Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative | $549,447 | Details |
Discovery | Drug Lead Identification | NTD (Chagas disease / Leishmaniasis) | Drug | 2017 | COMPLETE | Neglected Tropical Diseases Drug Discovery Booster III | Astellas Pharma Inc.,Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative | $1,498,328 | Details |
Discovery | Drug Target Validation | NTD (Chagas disease) | Drug | 2017 | COMPLETE | Target determination and exploratory research for discovery of new drugs against Chagas disease. | High Energy Accelerator Research Organization (KEK),London School of Hygiene and Tropical Medicine(LSHTM),National Institute of Advanced Industrial Science and Technology,Institute of Tropical Medicine (NEKKEN) Nagasaki University | $882,350 | Details |
Discovery | Drug Hit Identification | NTD (Chagas disease / Leishmaniasis) | Drug | 2017 | COMPLETE | Chagas disease and Leishmaniasis Screening between DNDi and Daiichi Sankyo Novare | Daiichi Sankyo RD Novare Co., Ltd.,Drugs for Neglected Diseases initiative | $119,000 | Details |
Discovery | Drug Hit Identification | NTD (Chagas disease / Leishmaniasis) | Drug | 2019 | COMPLETE | Screening project between Mitsubishi Tanabe and DNDi | Mitsubishi Tanabe Pharma Corporation,Drugs for Neglected Diseases initiative | $150,000 | Details |
Discovery | Drug Lead Identification | NTD (Chagas disease / Leishmaniasis) | Drug | 2020 | ACTIVE | Hit-To-Lead development for Neglected Tropical Diseases | Mitsubishi Tanabe Pharma Corporation,Drugs for Neglected Diseases initiative | $1,170,663 | Details |
Discovery | Drug Lead Identification | NTD (Soil-transmitted helminthiasis) | Drug | 2020 | ACTIVE | Cry5B optimization for Trichuris - whipworm | Kao Corporation,University of Massachusetts Medical School,PATH | $923,020 | Details |
Discovery | Drug Target Identification | NTD (Chagas disease) | Drug | 2020 | ACTIVE | Target validation and AI-guided identification of Trypanosoma cruzi phosphodiesterase inhibitors for the treatment of Chagas disease | Eisai Co., Ltd.,Universidad Nacional de La Plata (UNLP) | $710,077 | Details |
Discovery | Drug Hit Identification | NTD (Leishmaniasis) | Drug | 2020 | ACTIVE | Screening Program | University of Tokyo,Drugs for Neglected Diseases initiative | $168,759 | Details |
Discovery | Drug Hit Identification | NTD (Chagas disease / Leishmaniasis) | Drug | 2020 | COMPLETE | Screening Program | Daiichi Sankyo RD Novare Co., Ltd.,Drugs for Neglected Diseases initiative | $80,000 | Details |
Discovery | Drug Target Identification | NTD (Chagas disease) | Drug | 2021 | ACTIVE | Autophagy as a novel drug-development target for Chagas disease | National Institute of Advanced Industrial Science and Technology,Drugs for Neglected Diseases initiative | $989,200 | Details |
Discovery | Drug Hit Identification | NTD (Chagas disease) | Drug | 2021 | ACTIVE | Screening project between Daiichi Sankyo Company Limited and DNDi | Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative | $109,763 | Details |
Discovery | Drug Hit Identification | NTD (Chagas disease) | Drug | 2021 | ACTIVE | Screening project between Takeda Pharmaceutical Company Ltd. and DNDi | Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative | $89,946 | Details |
Discovery | Diagnostic Development Feasibility | NTD (Schistosomiasis) | Diagnostic | 2014 | COMPLETE | Development of a sensitive and specific point-of-care diagnostics for Asian zoonotic schistosomiasis | Graduate School of Agricultural and Life Sciences, The University of Tokyo,InBios International, Inc.,University of the Philippines,National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine | $779,036 | Details |
Discovery | Diagnostic Concept Development | NTD (Schistosomiasis) | Diagnostic | 2017 | COMPLETE | Novel diagnostics for schistosomiasis control: development of defined antigens for detection of Schistosoma infection-specific antibodies in blood and urine | Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Leiden University Medical Center,Lygature | $763,890 | Details |
Discovery | Diagnostic Concept Development | NTD (Mycetoma) | Diagnostic | 2019 | COMPLETE | MycEXomics aims to develop a field-friendly point-of-care diagnostic test for mycetoma | RIKEN,Hospital General de Mexico,Mycetoma Research Centre (MRC), University of Khartoum,Erasmus University Medical Center | $285,937 | Details |
Discovery | Diagnostic Concept Development | NTD (Buruli ulcer) | Diagnostic | 2020 | ACTIVE | Development of ‘all-in-one’ diagnostic kit for Buruli ulcer using lateral flow DNA-chromatography | Fasmac Co., Ltd.,Hope Commission International,Institut Pasteur de Côte d'Ivoire,Keio University School of Medicine,Nagasaki University,Raoul Follereau Institute Côte d’Ivoire,TBA Co., Ltd.,Teikyo University | $895,584 | Details |
Preclinical | Drug Preclinical development | Malaria | Drug | 2013 | TERMINATED | Development of ELQ300 as a long acting antimalarial | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) | $560,000 | Details |
Preclinical | Drug Preclinical development | Malaria | Drug | 2014 | COMPLETE | Preclinical and clinical development of (+)-SJ000557733, a novel inhibitor of Plasmodium ATP4 | Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),St. Jude Children’s Research Hospital | $3,768,922 | Details |
Preclinical | Drug Lead Optimization | Malaria | Drug | 2014 | COMPLETE | Lead optimization of a novel mechanism-of-action antimalarial | Eisai Co., Ltd.,Broad Institute | $2,997,525 | Details |
Preclinical | Drug Lead Optimization | Malaria | Drug | 2015 | COMPLETE | E209 a tetraoxane based rapidly acting antimalarial – candidate selection | Eisai Co., Ltd.,University of Liverpool,Liverpool School of Tropical Medicine | $207,753 | Details |
Preclinical | Drug Lead Optimization | Malaria | Drug | 2016 | COMPLETE | Development of a novel mechanism-of-action antimalarial drug with multistage activity | Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),Broad Institute | $1,999,993 | Details |
Preclinical | Drug Preclinical development | Malaria | Drug | 2016 | TERMINATED | DSM421 Clinical Development up to phase IIa GO | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) | $7,499,822 | Details |
Preclinical | Drug Lead Optimization | Malaria | Drug | 2016 | TERMINATED | Identification of pre-clinical candidate as an anti-malarial agent | Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV) | $1,761,309 | Details |
Preclinical | Drug Lead Optimization | Malaria | Drug | 2017 | COMPLETE | Lead optimization of potent Gwt1p inhibitors toward a new antimalarial drug with a novel mechanism of action | Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) | $2,639,670 | Details |
Preclinical | Drug Lead Optimization | Malaria | Drug | 2018 | ACTIVE | Preclinical development of a new class of Plasmodium DHODH inhibitor for the treatment of malaria | Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),Broad Institute | $4,214,187 | Details |
Preclinical | Drug Lead Optimization | Malaria | Drug | 2018 | COMPLETE | Mitsubishi Tanabe Lead Optimization of Anti-Malarials | Mitsubishi Tanabe Pharma Corporation,Medicines for Malaria Venture (MMV) | $1,922,475 | Details |
Preclinical | Drug Preclinical development | Malaria | Drug | 2018 | TERMINATED | Preclinical development of a novel mechanism-of-action antimalarial drug with multistage activity | Eisai Co., Ltd.,Broad Institute | $5,368,224 | Details |
Preclinical | Drug Preclinical development | Malaria | Drug | 2019 | ACTIVE | Preclinical studies of potent Gwt1p inhibitor toward IND for antimalarial agent with novel mechanism of action | Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) | $6,828,394 | Details |
Preclinical | Drug Preclinical development | Malaria | Drug | 2019 | ACTIVE | Preclinical and Clinical Development of SJ733, a Novel PfATP4 Inhibitor for the Treatment of Severe Malaria | Eisai Co., Ltd.,University of Kentucky | $5,590,091 | Details |
Preclinical | Drug Lead Optimization | Malaria | Drug | 2020 | ACTIVE | Structured-based approach to develop a novel mechanism-of-action antimalarial with multistage activity | Eisai Co., Ltd.,International Centre for Genetic Engineering and Biotechnology ,The Scripps Research Institute,Broad Institute | $4,127,236 | Details |
Preclinical | Drug Lead Optimization | Malaria | Drug | 2020 | ACTIVE | Optimisation of multistage inhibitors of Plasmodium falciparum lysyl t-RNA synthetase for the treatment of malaria | Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),University of Dundee | $3,538,738 | Details |
Preclinical | Drug Lead Optimization | Malaria | Drug | 2021 | ACTIVE | Preclinical development of a monoclonal antibody to prevent P. falciparum malaria | Ehime University,Eisai Co., Ltd.,GlaxoSmithKline plc.,PATH | $5,386,616 | Details |
Preclinical | Vaccine Lead Optimization | Malaria | Vaccine | 2015 | COMPLETE | Lead optimization of an evolution-proof malaria transmission-blocking vaccine immunogen that is based on a mosquito protein target and effective against both P.falciparum and P. vivax | CellFree Sciences Co. Ltd.,Infectious Disease Research Institute,The University of Florida | $419,285 | Details |
Preclinical | Vaccine Preclinical Development | Malaria | Vaccine | 2017 | COMPLETE | Process Development and Clinical Manufacturing of an Immuno-focused, Mosquito-based Pan-malaria transmission-blocking vaccine: AnAPN1 v. 2.0 | CellFree Sciences Co. Ltd.,Centre Pasteur du Cameroun (CPC),Hamamatsu Pharma Research,Infectious Disease Research Institute,Ology Bioservices Inc.,The University of Florida | $3,484,217 | Details |
Preclinical | Vaccine Lead Optimization | Malaria | Vaccine | 2018 | COMPLETE | Further development of a new asexual blood-stage malaria vaccine candidate | Ehime University,iBET,European Vaccine Initiative (EVI) | $930,571 | Details |
Preclinical | Vaccine Preclinical Development | Malaria | Vaccine | 2019 | ACTIVE | Preclinical development of malaria transmission-blocking vaccine candidate Pfs230D1+ formulated with SA-1 adjuvant | Ehime University,Sumitomo Dainippon Pharma Co., Ltd.,PATH | $5,007,283 | Details |
Preclinical | Vaccine Preclinical Development | Malaria | Vaccine | 2020 | ACTIVE | First-In-Human Trial of the Pan-Malaria Transmission-Blocking Vaccine AnAPN1 | Ajinomoto Bio-Pharma Services, GeneDesign (GeneDesign),CellFree Sciences Co. Ltd.,Centre de Recherches Médicales de Lambaréné (CERMEL) ,University of Tübingen (UKT) ,The University of Florida | $6,486,223 | Details |
Preclinical | Vaccine Preclinical Development | Malaria | Vaccine | 2021 | ACTIVE | Clinical development of placental malaria vaccine candidates | Ehime University,Groupe de Recherche Action en Santé (GRAS),Institut de recherche pour le développement,Institut national de la santé et de la recherche médicale,Noguchi Memorial Institute for Medical Research,University of Copenhagen (UCPH) ,European Vaccine Initiative (EVI) | $4,692,924 | Details |
Preclinical | Drug Lead Optimization | Tuberculosis | Drug | 2017 | ACTIVE | Lead optimization of novel azetidine-based tryptophan synthase inhibitors as new mechanism of action treatment of tuberculosis | Eisai Co., Ltd.,Colorado State University,The Global Alliance for TB Drug Development,The University of Chicago,Broad Institute | $2,003,324 | Details |
Preclinical | Vaccine Lead Optimization | Tuberculosis | Vaccine | 2013 | TERMINATED | Development of rhPIV2 as a Potential New TB Vaccine Candidate | National Institutes of Biomedical Innovation, Health and Nutrition,Aeras | $5,649,620 | Details |
Preclinical | Vaccine Lead Optimization | Tuberculosis | Vaccine | 2013 | TERMINATED | Development of recombinant hPIV2 virus vector as a new TB vaccine | National Institutes of Biomedical Innovation, Health and Nutrition,Aeras | $700,000 | Details |
Preclinical | Drug Lead Optimization | NTD (Lymphatic filariasis / Onchocerciasis) | Drug | 2013 | COMPLETE | Anti-Wolbachia targeted macrofilaricidal drug discovery-lead optimization of lead series chemotypes to deliver novel pre-clinical candidates | Eisai Co., Ltd.,University of Liverpool,Liverpool School of Tropical Medicine | $1,093,166 | Details |
Preclinical | Drug Lead Optimization | NTD (Leishmaniasis) | Drug | 2014 | COMPLETE | Lead optimization of the aminopyrazole series for visceral leishmaniasis | Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative | $4,022,552 | Details |
Preclinical | Drug Lead Optimization | NTD (Soil-transmitted helminthiasis) | Drug | 2015 | COMPLETE | Cry5B consortium for soil-transmitted helminths | Meiji Seika Pharma Co., Ltd.,University of Massachusetts Medical School,PATH | $1,002,996 | Details |
Preclinical | Drug Preclinical development | NTD (Leishmaniasis) | Drug | 2015 | COMPLETE | Preclinical efficacy of CpG D35 combination therapy for treatment of complicated cutaneous leishmaniasis | GeneDesign, Inc,Drugs for Neglected Diseases initiative | $687,715 | Details |
Preclinical | Drug Preclinical development | NTD (Dengue) | Drug | 2016 | COMPLETE | Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes | Chugai Pharmaceutical Co., Ltd.,A∗STAR′s Singapore Immunology Network (SIgN) | $5,348,894 | Details |
Preclinical | Drug Preclinical development | NTD (Leishmaniasis) | Drug | 2016 | COMPLETE | Preclinical development of CpG D35 for combined treatment of cutaneous leishmaniasis | GeneDesign, Inc,Drugs for Neglected Diseases initiative | $4,918,672 | Details |
Preclinical | Drug Preclinical development | NTD (Leishmaniasis) | Drug | 2017 | TERMINATED | Preclinical development and phase I activities on a selected aminopyrazole compound for visceral leishmaniasis | Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative | $6,047,757 | Details |
Preclinical | Drug Preclinical development | NTD (Dengue) | Drug | 2018 | COMPLETE | Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes | Chugai Pharmaceutical Co., Ltd.,A∗STAR′s Singapore Immunology Network (SIgN) | $4,892,737 | Details |
Preclinical | Drug Preclinical development | NTD (Lymphatic filariasis / Onchocerciasis) | Drug | 2019 | ACTIVE | Development of AWZ1066S, A Small Molecule anti-Wolbachia Candidate Macrofilaricide Drug | Eisai Co., Ltd.,University of Liverpool,Liverpool School of Tropical Medicine | $4,335,812 | Details |
Preclinical | Drug Lead Optimization | NTD (Chagas disease) | Drug | 2019 | COMPLETE | Lead optimization of a candidate series active against Chagas Disease | Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative | $4,318,565 | Details |
Preclinical | Drug Preclinical development | NTD (Leishmaniasis) | Drug | 2020 | ACTIVE | Preclinical development of DNDI-6174, a drug candidate for leishmaniasis | Eisai Co., Ltd.,Drugs for Neglected Diseases initiative | $6,122,938 | Details |
Preclinical | Drug Lead Optimization | NTD (Leishmaniasis) | Drug | 2020 | ACTIVE | Lead optimization and preclinical candidate selection from the NTD Drug Discovery Booster series S07 for visceral leishmaniasis | Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative | $2,257,442 | Details |
Preclinical | Vaccine Preclinical Development | NTD (Dengue) | Vaccine | 2014 | COMPLETE | Development of a Live Attenuated Tetravalent Dengue Vaccine | The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN),Mahidol University | $3,450,276 | Details |
Preclinical | Vaccine Preclinical Development | NTD (Chagas disease) | Vaccine | 2014 | COMPLETE | Adjuvant Technologies to Advance Chagas Disease Vaccine Development | Eisai Co., Ltd.,Baylor College of Medicine (BCM),Aeras,Sabin Vaccine Institute | $2,000,000 | Details |
Preclinical | Vaccine Lead Optimization | NTD (Leishmaniasis) | Vaccine | 2015 | COMPLETE | Live attenuated prophylactic vaccine for leishmaniasis | Institute of Tropical Medicine (NEKKEN) Nagasaki University ,McGill University ,The Ohio State University | $1,832,967 | Details |
Preclinical | Vaccine Preclinical Development | NTD (Dengue) | Vaccine | 2015 | COMPLETE | Preclinical development of MVDVax, a new dengue vaccine | Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Institut Pasteur,European Vaccine Initiative (EVI) | $612,902 | Details |
Preclinical | Vaccine Preclinical Development | NTD (Leishmaniasis) | Vaccine | 2016 | COMPLETE | Preclinical and preparation of early clinical testing of a new vaccine candidate against cutaneous leishmaniasis | Nagasaki University,London School of Hygiene and Tropical Medicine(LSHTM),Mologen ,Charité –Universitätsmedizin Berlin,European Vaccine Initiative (EVI) | $4,096,664 | Details |
Preclinical | Vaccine Preclinical Development | NTD (Dengue) | Vaccine | 2016 | COMPLETE | Development of novel dengue virus-like particle (VLP) vaccines against all four serotypes | Institute of Tropical Medicine (NEKKEN) Nagasaki University ,National Institute of Infectious Diseases,VLP Therapeutics | $986,540 | Details |
Preclinical | Vaccine Preclinical Development | NTD (Dengue) | Vaccine | 2018 | ACTIVE | The development and production of cGMP lots of a novel tetravalent dengue virus-like particle (VLP) vaccine | Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Johns Hopkins University,Latham BioPharm Group,National Institute of Infectious Diseases,VLP Therapeutics | $4,422,091 | Details |
Preclinical | Vaccine Lead Optimization | NTD (Leishmaniasis) | Vaccine | 2018 | ACTIVE | Live attenuated prophylactic vaccine for leishmaniasis | Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Gennova Biopharmaceuticals Ltd.,McGill University ,The Ohio State University | $3,998,989 | Details |
Preclinical | Vaccine Preclinical Development | NTD (Leishmaniasis) | Vaccine | 2018 | COMPLETE | Immune therapy to prevent VL complications | University of Tokyo,International Center for Diarrheal Disease Research Bangladesh,Infectious Disease Research Institute | $558,315 | Details |
Preclinical | Vaccine Lead Optimization | NTD (Chagas disease) | Vaccine | 2019 | ACTIVE | Optimization and pre-clinical development of a Trypanosoma cruzi Cyp19 knock-out strain as a live vaccine for Chagas disease. | Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Ohio University,The Ohio State University | $1,097,927 | Details |
Preclinical | Diagnostic Product Design | NTD (Leishmaniasis) | Diagnostic | 2019 | ACTIVE | Production, validation and use of Leishmanin skin test (LST) for detection of Leishmania exposure and immunity | Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Gennova Biopharmaceuticals Ltd.,McGill University ,U.S. Food and Drug Administration,The Ohio State University | $2,257,699 | Details |
Clinical | Drug Clinical Phase2 | Malaria | Drug | 2013 | COMPLETE | Development of DSM265 as a long acting antimalarial compound | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) | $2,538,796 | Details |
Clinical | Drug Clinical Phase1 | Malaria | Drug | 2014 | COMPLETE | Testing DSM265, a novel antimalarial acting through DHODH, in combination with OZ439 | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) | $1,290,883 | Details |
Clinical | Drug Clinical Phase2 | Malaria | Drug | 2015 | COMPLETE | Commercial formulation development of DSM265 | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) | $1,905,341 | Details |
Clinical | Drug Clinical Phase2 | Malaria | Drug | 2016 | ACTIVE | Phase 2 Trial of SJ733, a Novel PfATP4 Inhibitor for Malaria | Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),University of Kentucky | $4,500,001 | Details |
Clinical | Drug Clinical Phase2 | Malaria | Drug | 2016 | COMPLETE | Formulation Optimization Work on DSM265 | Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) | $1,589,999 | Details |
Clinical | Vaccine Phase1 Clinical Development | Malaria | Vaccine | 2013 | COMPLETE | Clinical Development of BK-SE36/CpG Malaria Vaccine | Research Institute for Microbial Diseases (RIMD), Osaka University,Gulu University, Uganda | $714,500 | Details |
Clinical | Vaccine Phase1 Clinical Development | Malaria | Vaccine | 2014 | COMPLETE | Clinical development of the BK-SE36 malaria vaccine candidate | Research Institute for Microbial Diseases (RIMD), Osaka University,Centre National de Recherche et de Formation sur le Paludisme (CNRFP),European Vaccine Initiative (EVI) | $999,999 | Details |
Clinical | Vaccine Phase1 Clinical Development | Malaria | Vaccine | 2016 | COMPLETE | Clinical Development of BK-SE36/CpG Malaria Vaccine: safety evaluation of BK-SE36/CpG in the malaria endemic population | Medical Center for Translational Research (MTR), Osaka University Hospital,Institut de Recherche en Sciences de la Santé (IRSS),Nobelpharma Co., Ltd.,Research Institute for Microbial Diseases (RIMD), Osaka University,European Vaccine Initiative (EVI) | $2,781,588 | Details |
Clinical | Vaccine Phase1 Clinical Development | Malaria | Vaccine | 2019 | ACTIVE | Preparatory phase II for the malaria vaccine candidate NPC-SE36/CpG | Nobelpharma Co., Ltd.,Groupe de Recherche Action en Santé (GRAS),Research Institute for Microbial Diseases (RIMD), Osaka University,European Vaccine Initiative (EVI) | $1,870,777 | Details |
Clinical | Diagnostic Product Validation | Malaria | Diagnostic | 2015 | COMPLETE | Development of a fully automated malaria diagnostic system and field evaluation for practical use | Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Juntendo University,Kenya Medical Research Institute (KEMRI-CGHR),Malaria No More Japan (MNMJ),National Institute of Advanced Industrial Science and Technology,Panasonic Corporation | $964,500 | Details |
Clinical | Diagnostic Product Development | Malaria | Diagnostic | 2019 | COMPLETE | Commercial Development of a Saliva-based Malaria Asymptomatic and Asexual Rapid Test (SMAART-1) | CellFree Sciences Co. Ltd.,ERADA Technology Alliance, Ltd.,Frontier Institute Co., Ltd.,Oasis Diagnostics Corp.,The University of Florida | $1,382,696 | Details |
Clinical | Vaccine Phase2 Clinical Development | Tuberculosis | Vaccine | 2015 | COMPLETE | DAR-901 whole cell booster vaccine to prevent TB infection in adolescents (“DAR-PIA”) | Tokyo Medical and Dental University,Muhimbili University of Health and Allied Sciences (MUHAS),Geisel School of Medicine at Dartmouth | $1,423,590 | Details |
Clinical | Diagnostic Product Validation | Tuberculosis | Diagnostic | 2015 | COMPLETE | Highly Sensitive POC TB-LAM Rapid Diagnostic Test | Fujifilm Corporation ,Foundation for Innovative New Diagnostics (FIND) | $2,160,577 | Details |
Clinical | Diagnostic Product Validation | Tuberculosis | Diagnostic | 2017 | ACTIVE | Fujifilm SILVAMP TB LAM – A Sensitive point-of-care Tuberculosis Test | Fujifilm Corporation ,Foundation for Innovative New Diagnostics (FIND) | $4,217,169 | Details |
Clinical | Diagnostic Product Validation | Tuberculosis | Diagnostic | 2020 | COMPLETE | Product Development of LFA platform for improving sensitivity of Point-of-Care assays for infectious disease with main focus on Tuberculosis | Asahi Kasei Corporation,Biopromic AB | $2,266,257 | Details |
Clinical | Diagnostic Product Development | Tuberculosis | Diagnostic | 2021 | ACTIVE | Viability & Value of the Lung Flute ECO for Sputum Sample Collection and Tuberculosis Testing in Vulnerable Groups (3V Trial) | Acoustic Innovations (AI),Center for Health Promotion and Research (CHPR),Institute of Tropical Medicine (ITM),Research Institute of Tuberculosis | $833,738 | Details |
Clinical | Drug Clinical Phase2 | NTD (Chagas disease) | Drug | 2013 | COMPLETE | A new treatment for Chagas disease | Eisai Co., Ltd.,Drugs for Neglected Diseases initiative | $3,840,892 | Details |
Clinical | Drug Clinical Phase1 | NTD (Schistosomiasis) | Drug | 2013 | COMPLETE | Development and registration of a new praziquantel pediatric formulation for the treatment of schistosomiasis | Astellas Pharma Inc.,Farmanguinhos,Merck KGaA,Simcyp Limited,Swiss Tropical and Public Health Institute,Lygature | $1,864,898 | Details |
Clinical | Drug Clinical Phase2 | NTD (Schistosomiasis) | Drug | 2014 | COMPLETE | Development and registration of a new praziquantel pediatric formulation for the treatment of schistosomiasis | Astellas Pharma Inc.,Farmanguinhos,Merck KGaA,Simcyp Limited,Swiss Tropical and Public Health Institute,Lygature | $4,856,513 | Details |
Clinical | Drug Clinical Phase3 | NTD (Schistosomiasis) | Drug | 2016 | COMPLETE | Development and registration of a new pediatric praziquantel formulation for the treatment of schistosomiasis in preschool-aged children | Astellas Pharma Inc.,Farmanguinhos,Merck KGaA,Schistosomiasis Control Initiative (SCI),Simcyp Limited,Swiss Tropical and Public Health Institute,Lygature | $4,679,698 | Details |
Clinical | Drug Clinical Phase2 | NTD (Mycetoma) | Drug | 2017 | ACTIVE | Mycetoma Treatment, Fosravuconazole Clinical Trial | Eisai Co., Ltd.,Drugs for Neglected Diseases initiative | $2,526,217 | Details |
Clinical | Drug Registration | NTD (Schistosomiasis) | Drug | 2018 | ACTIVE | Treating schistosomiasis in preschool-aged children: development, registration and access to L-praziquantel orally disintegrating tablet formulation | Astellas Pharma Inc.,Farmanguinhos,Kenya Medical Research Institute (KEMRI-CGHR),Merck KGaA,Schistosomiasis Control Initiative (SCI),Swiss Tropical and Public Health Institute,Université Félix Houphouët Boigny (UFHB),Lygature | $4,523,295 | Details |
Clinical | Drug Clinical Phase1 | NTD (Leishmaniasis) | Drug | 2020 | ACTIVE | Clinical development of CpG-D35 for combined treatment of cutaneous leishmaniasis | Ajinomoto Bio-Pharma Services, GeneDesign (GeneDesign),University of Tokyo,Drugs for Neglected Diseases initiative | $6,923,997 | Details |
Clinical | Drug Registration | NTD (Schistosomiasis) | Drug | 2020 | ACTIVE | Adoption of Levo-Praziquantel 150mg for schistosomiasis by endemic countries | Astellas Pharma Inc.,Kenya Medical Research Institute (KEMRI-CGHR),Klinikum rechts der Isar der Technischen Universität München, Department of Neurology (MRI),Merck KGaA,SCI Foundation,Swiss Tropical and Public Health Institute,Université Félix Houphouët Boigny (UFHB),Lygature | $2,622,542 | Details |
Clinical | Drug Clinical Phase2 | NTD (Lymphatic filariasis / Onchocerciasis) | Drug | 2022 | ACTIVE | Phase II Clinical Development of AWZ1066S, a Small Molecule anti-Wolbachia Candidate Macrofilaricide Drug | Eisai Co., Ltd.,University Hospital of Bonn (UKB),University of Buea (UoB) ,University of Liverpool,Liverpool School of Tropical Medicine | $7,960,044 | Details |
Clinical | Diagnostic Product Development | NTD (Schistosomiasis) | Diagnostic | 2020 | ACTIVE | A schistosomiasis rapid diagnostic test to support control programmes in monitoring treatment impact and reassessment mapping | Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Leiden University Medical Center,Merck KGaA,Foundation for Innovative New Diagnostics (FIND) | $3,733,973 | Details |
Clinical | Diagnostic Product Development | NTD (Buruli ulcer) | Diagnostic | 2020 | ACTIVE | A Buruli ulcer mycolactone (BU-MYCOLAC) rapid diagnostic test to enhance early diagnosis and treatment | Nagasaki University,Drugs and Diagnostics for Tropical Diseases,Swiss Tropical and Public Health Institute,Foundation for Innovative New Diagnostics (FIND) | $1,836,107 | Details |
Clinical | Diagnostic Product Validation | NTD (Chagas disease) | Diagnostic | 2020 | ACTIVE | Field validation of Trypanosoma cruzi-LAMP: a molecular point-of-care test for the control of congenital Chagas disease | Eiken Chemical Co., Ltd.,Centro para el Desarrollo de Investigación Científica (CEDIC) ,Ciencia y Estudios Aplicados Para el Desarrollo en Salud y Medio Ambiente (CEADES) ,AI Biosciences Inc. ,Fundacion Mundo Sano,Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (CONICET-INGEBI),Nagasaki University,Barcelona Institute for Global Health (ISGLOBAL) | $1,471,273 | Details |
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Screening Program
- Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $104,264
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Screening Program
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
- Awarded Amount: $73,940
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Screening Program
- Partner: Kitasato Institute,Medicines for Malaria Venture (MMV)
- Awarded Amount: $570
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Screening Program
- Partner: Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $241,372
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Screening Program
- Partner: Institute of Microbial Chemistry,Medicines for Malaria Venture (MMV)
- Awarded Amount: $11,286
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2014
- Status:
- Project: Screening Program
- Partner: Mitsubishi Tanabe Pharma Corporation,Medicines for Malaria Venture (MMV)
- Awarded Amount: $186,420
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2014
- Status:
- Project: Screening Program
- Partner: Sumitomo Dainippon Pharma Co., Ltd.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $137,883
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2014
- Status:
- Project: Design and Cost-effective de novo Synthesis of Aza-artemisinins
- Partner: Kitasato Institute,Medicines for Malaria Venture (MMV),Hokkaido University
- Awarded Amount: $60,000
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2014
- Status:
- Project: Identification of lead compounds for anti-Malarial agent
- Partner: Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $636,941
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Hit-to-Lead Discovery for New Anti-malarials in Collaboration between MMV and Eisai
- Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $779,760
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Antimalarial hits from whole cell screening
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
- Awarded Amount: $764,033
- Development Stage: Discovery
- Current Stage: Drug Target Validation
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Proteasome inhibitors as new potent resistance-reversing antimalarials
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV),The University of Melbourne
- Awarded Amount: $297,133
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Screening Program
- Partner: Daiichi Sankyo RD Novare Co., Ltd.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $150,000
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Screening Program
- Partner: Op Bio Factory Co., Ltd.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $68,400
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: New Hit-to-Lead Activity for New Anti-Malarias between MMV and Eisai
- Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $750,000
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: Mitsubishi Tanabe malaria Hit-to-Lead
- Partner: Mitsubishi Tanabe Pharma Corporation,Medicines for Malaria Venture (MMV)
- Awarded Amount: $618,222
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: New Hit-to-Lead Activity for New Anti-Malarias between MMV and Takeda
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
- Awarded Amount: $483,360
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2017
- Status:
- Project: HTL for selective Plasmodium proteasome inhibitors as new potent resistance-reversing antimalarials
- Partner: Takeda Pharmaceutical Company Limited,The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute,Medicines for Malaria Venture (MMV)
- Awarded Amount: $461,245
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2017
- Status:
- Project: New Hit-to-Lead Activity for New Anti-Malaria drugs between MMV and Sumitomo Dainippon Pharma
- Partner: Sumitomo Dainippon Pharma Co., Ltd.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $445,500
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2017
- Status:
- Project: Screening Program
- Partner: Astellas Pharma Inc.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $65,836
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2017
- Status:
- Project: Screening Program
- Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $49,500
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2018
- Status:
- Project: New Hit-to-Lead Activity for New Anti-Malarials between MMV and Takeda
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
- Awarded Amount: $528,000
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2018
- Status:
- Project: Screening Program
- Partner: University of Tokyo,Medicines for Malaria Venture (MMV)
- Awarded Amount: $150,000
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2019
- Status:
- Project: Development of nucleoside sulfamates as novel antimalarials
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV),The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute
- Awarded Amount: $1,016,129
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2019
- Status:
- Project: Proteasome inhibitors as new potent antimalarials
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV),The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute
- Awarded Amount: $526,140
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2019
- Status:
- Project: Screening project between Takeda and MMV
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
- Awarded Amount: $41,962
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Hit-to-lead development of new antimalarial compounds from DDI library
- Partner: University of Tokyo,Medicines for Malaria Venture (MMV)
- Awarded Amount: $1,167,442
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Pioneering antisense oligonucleotides as long-acting malaria prophylactics
- Partner: Eisai Co., Ltd.,University of California, San Diego (UCSD)
- Awarded Amount: $922,972
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Screening Program
- Partner: Daiichi Sankyo, Inc.,Eisai Co., Ltd.,Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
- Awarded Amount: $210,936
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Prolyl tRNA Synthetase Inhibitors for New Antimalarials
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
- Awarded Amount: $547,268
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Screening Program
- Partner: Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $122,013
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2021
- Status:
- Project: Hit-to-Lead development of novel Astellas compounds with antimalarial activity
- Partner: Astellas Pharma Inc.,Medicines for Malaria Venture (MMV),TCG Lifesciences Private Limited. (TCGLS)
- Awarded Amount: $1,317,435
- Development Stage: Discovery
- Current Stage: Drug Target Identification
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2021
- Status:
- Project: Identification and Validation of potential Plasmodium E3 Ligases for PROTAC Platform
- Partner: FIMECS, Inc.,National Center for Genetic Engineering and Biotechnology (BIOTEC)
- Awarded Amount: $838,587
- Development Stage: Discovery
- Current Stage: Vaccine Technology Platform Identification
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2013
- Status:
- Project: Accelerating Development of Vaccines for Malaria Elimination Using a Novel Clinical Target Validation Approach
- Partner: CellFree Sciences Co. Ltd.,Ehime University,PATH Malaria Vaccine Initiative
- Awarded Amount: $591,396
- Development Stage: Discovery
- Current Stage: Vaccine Technology Platform Identification
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2014
- Status:
- Project: Accelerating Development of Transmission-Blocking Vaccines for Malaria Elimination Using a Novel Vaccine Candidate
- Partner: Ehime University,PATH Malaria Vaccine Initiative
- Awarded Amount: $766,098
- Development Stage: Discovery
- Current Stage: Vaccine Antigen Identification
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2016
- Status:
- Project: A Vaccine to Block Malaria Transmission: Pfs230 Antigen Design and Display
- Partner: Ehime University,PATH Malaria Vaccine Initiative
- Awarded Amount: $595,650
- Development Stage: Discovery
- Current Stage: Vaccine Antigen Identification
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2017
- Status:
- Project: Identification of Vaccine Targets that Will Block the Interaction of Plasmodium falciparum Malaria Parasites with a Complement Regulator
- Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Antigen Discovery, Inc.,The Pennsylvania State University
- Awarded Amount: $881,900
- Development Stage: Discovery
- Current Stage: Vaccine Vaccine Concept Development
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2019
- Status:
- Project: Made-in-Japan next-generation vaccine platform effective for multistage Plasmodium for infants
- Partner: Hokkaido University,Jichi Medical University,Toyama University,University of Cambridge,Kanazawa University
- Awarded Amount: $526,900
- Development Stage: Discovery
- Current Stage: Vaccine Antigen Identification
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2019
- Status:
- Project: Co-delivery of Pfs230C1 and CSP with CoPoP, a versatile, potent liposomal adjuvant system for multistage malaria vaccine
- Partner: Ehime University,University at Buffalo, The State University of New York,PATH Malaria Vaccine Initiative
- Awarded Amount: $972,951
- Development Stage: Discovery
- Current Stage: Vaccine Technology Platform Identification
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2019
- Status:
- Project: Development of a novel Pvs25 nucleoside-modified mRNA vaccine that induces potent and long-lasting transmission blocking immunity
- Partner: Tokyo Medical and Dental University,University of Pennsylvania,Mahidol University
- Awarded Amount: $960,771
- Development Stage: Discovery
- Current Stage: Vaccine Antigen Identification
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2020
- Status:
- Project: Evaluation of a malaria vaccine candidate comprised of full-length recombinant CSP formulated with SA-1 adjuvant, using RTS,S/AS01 as a benchmark
- Partner: Ehime University,Sumitomo Dainippon Pharma Co., Ltd.,PATH
- Awarded Amount: $999,733
- Development Stage: Discovery
- Current Stage: Vaccine Antigen Identification
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2021
- Status:
- Project: Development of a Plasmodium vivax multistage vaccine effective both for protection and transmission blocking
- Partner: Hokkaido University,Instituto Leônidas & Maria Deane (ILMD) and The Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD),Jichi Medical University,Kyoto University,Toyama University,University of Cambridge,Kanazawa University
- Awarded Amount: $698,170
- Development Stage: Discovery
- Current Stage: Diagnostic Technical Feasibility
- Disease: Malaria
- Intervention: Diagnostic
- RFP Year: 2015
- Status:
- Project: Development of serological biomarkers as indicators of recent and asymptomatic infections for innovative tools to accelerate malaria elimination
- Partner: CellFree Sciences Co. Ltd.,Foundation for Innovative New Diagnostics (FIND),Proteo-Science Centre, Ehime University,The Walter and Eliza Hall Institute of Medical Research
- Awarded Amount: $993,030
- Development Stage: Discovery
- Current Stage: Diagnostic Concept Development
- Disease: Malaria
- Intervention: Diagnostic
- RFP Year: 2017
- Status:
- Project: Towards rapid diagnosis of Plasmodium vivax malaria hypnozoite infection
- Partner: National Institute of Technology, Kumamoto College,Biomedical Primate Research Centre,Institute of Tropical Medicine (NEKKEN) Nagasaki University
- Awarded Amount: $728,830
- Development Stage: Discovery
- Current Stage: Diagnostic Technical Feasibility
- Disease: Malaria
- Intervention: Diagnostic
- RFP Year: 2020
- Status:
- Project: Towards the rapid diagnosis of malaria hypnozoite infection: feasibility studies
- Partner: National Institute of Technology, Kumamoto College,Biomedical Primate Research Centre,Institute of Tropical Medicine (NEKKEN) Nagasaki University
- Awarded Amount: $999,809
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Screening Program
- Partner: SHIONOGI & CO., LTD.,The Global Alliance for TB Drug Development
- Awarded Amount: $105,450
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Screening Program
- Partner: Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development
- Awarded Amount: $55,550
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Screening Program
- Partner: Daiichi Sankyo, Inc.,The Global Alliance for TB Drug Development
- Awarded Amount: $135,300
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2014
- Status:
- Project: Screening Program
- Partner: Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development
- Awarded Amount: $150,000
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2014
- Status:
- Project: Screening Program
- Partner: Op Bio Factory Co., Ltd.,The Global Alliance for TB Drug Development
- Awarded Amount: $150,000
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Hit-to-Lead Development of anti-TB Phenotypic Screening Hits
- Partner: The Research Institute of Tuberculosis, Japan Anti-tuberculosis Association,The Global Alliance for TB Drug Development,SHIONOGI & CO., LTD.
- Awarded Amount: $999,720
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Development of Phenotypic Screening Hits against Mycobacterium tuberculosis
- Partner: Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development
- Awarded Amount: $792,165
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Screening Program
- Partner: Toyama Prefectural University,The Global Alliance for TB Drug Development,HYPHAGENESIS INC.
- Awarded Amount: $150,000
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Screening Program
- Partner: Chugai Pharmaceutical Co., Ltd.,The Global Alliance for TB Drug Development
- Awarded Amount: $150,000
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Screening Program
- Partner: Mitsubishi Tanabe Pharma Corporation,The Global Alliance for TB Drug Development
- Awarded Amount: $132,000
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Screening Program
- Partner: Sumitomo Dainippon Pharma Co., Ltd.,The Global Alliance for TB Drug Development
- Awarded Amount: $79,200
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Identification of lead compounds as novel anti‐TB agents
- Partner: Daiichi Sankyo, Inc.,The Global Alliance for TB Drug Development
- Awarded Amount: $908,231
- Development Stage: Discovery
- Current Stage: Drug Target Validation
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: Host-directed drug targeting against tuberculosis
- Partner: RIKEN,International Centre for Genetic Engineering and Biotechnology
- Awarded Amount: $204,990
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2017
- Status:
- Project: Screening Program
- Partner: Astellas Pharma Inc.,The Global Alliance for TB Drug Development
- Awarded Amount: $99,986
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2018
- Status:
- Project: Hit-to-Lead Development of Novel anti-TB Natural Products
- Partner: Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development
- Awarded Amount: $1,192,440
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2018
- Status:
- Project: Screening Program
- Partner: Fujifilm Corporation ,The Global Alliance for TB Drug Development
- Awarded Amount: $110,000
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2019
- Status:
- Project: Hit-to-Lead Development of Phenotypic and Mechanism-based Screen Hits
- Partner: Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development
- Awarded Amount: $1,112,058
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2019
- Status:
- Project: Hit-to-Lead Development of Phenotypic Screening Hits
- Partner: Chugai Pharmaceutical Co., Ltd.,The Global Alliance for TB Drug Development
- Awarded Amount: $953,159
- Development Stage: Discovery
- Current Stage: Drug Target Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Identification of novel dual-acting bactericidal drug targets against Mycobacterium tuberculosis
- Partner: Hokkaido University,Harvard University,Nagoya University,Research Institute of Tuberculosis ,University of Minnesota ,Fujita Health University
- Awarded Amount: $974,619
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Hit-to-Lead Development of Hits Identified in the Phenotypic Screening against Mycobacterium tuberculosis (Mtb)
- Partner: Astellas Pharma Inc.,The Global Alliance for TB Drug Development
- Awarded Amount: $801,363
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Screening Program
- Partner: Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development
- Awarded Amount: $118,300
- Development Stage: Discovery
- Current Stage: Vaccine Vaccine Concept Development
- Disease: Tuberculosis
- Intervention: Vaccine
- RFP Year: 2016
- Status:
- Project: Development of a new mucosal vaccine for Tuberculosis using antibody engineering
- Partner: University of Tokyo,Universidad de Concepcion,Instituto de Nutricion “Salvador Zubiran”,Universiti Sains Malaysia
- Awarded Amount: $373,561
- Development Stage: Discovery
- Current Stage: Diagnostic Concept Development
- Disease: Tuberculosis
- Intervention: Diagnostic
- RFP Year: 2018
- Status:
- Project: Development of LFA platform for improving sensitivity of Point-of-Care assays for infectious disease with main focus on Tuberculosis and Malaria.
- Partner: Asahi Kasei Corporation,Biopromic AB
- Awarded Amount: $1,000,000
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: NTD (Chagas disease)
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Optimization of Diversity-Oriented Synthesis (DOS)-derived trypanocidal small molecule ML341 towards investigational new drug status for Chagas disease
- Partner: Eisai Co., Ltd.,Broad Institute
- Awarded Amount: $500,000
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: NTD (Chagas disease / Leishmaniasis)
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Screening Program
- Partner: Eisai Co., Ltd.,Drugs for Neglected Diseases initiative
- Awarded Amount: $75,582
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: NTD (Chagas disease / Leishmaniasis)
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Screening Program
- Partner: Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
- Awarded Amount: $75,582
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: NTD (Chagas disease / Leishmaniasis)
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Screening Program
- Partner: Kitasato Institute,Drugs for Neglected Diseases initiative
- Awarded Amount: $0
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: NTD (Chagas disease / Leishmaniasis)
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Screening Program
- Partner: Institute of Microbial Chemistry,Drugs for Neglected Diseases initiative
- Awarded Amount: $7,558
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: NTD (Chagas disease / Leishmaniasis)
- Intervention: Drug
- RFP Year: 2014
- Status:
- Project: Neglected Tropical Diseases Drug Discovery Booster
- Partner: Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
- Awarded Amount: $795,437
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: NTD (Chagas disease)
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Screening Program
- Partner: Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative
- Awarded Amount: $210,050
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: NTD (Leishmaniasis)
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Screening Program
- Partner: Eisai Co., Ltd.,Drugs for Neglected Diseases initiative
- Awarded Amount: $31,000
- Development Stage: Discovery
- Current Stage: Drug Target Validation
- Disease: NTD (Chagas disease / Leishmaniasis)
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: Targeting bromodomains for novel anti-parasitic mechanisms of action for malaria, Chagas disease, leishmaniasis and cryptosporidiosis
- Partner: RIKEN,McGill University ,Medicines for Malaria Venture (MMV),Structural Genomics Consortium at University of Toronto,The University of Melbourne,Drugs for Neglected Diseases initiative
- Awarded Amount: $982,436
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: NTD (Chagas disease)
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: Identification of lead compounds for Leishmania donovani and/or Trypanosoma cruzi
- Partner: Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative
- Awarded Amount: $780,000
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: NTD (Chagas disease / Leishmaniasis)
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: Neglected Tropical Diseases Drug Discovery Booster II
- Partner: Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
- Awarded Amount: $549,447
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: NTD (Chagas disease / Leishmaniasis)
- Intervention: Drug
- RFP Year: 2017
- Status:
- Project: Neglected Tropical Diseases Drug Discovery Booster III
- Partner: Astellas Pharma Inc.,Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
- Awarded Amount: $1,498,328
- Development Stage: Discovery
- Current Stage: Drug Target Validation
- Disease: NTD (Chagas disease)
- Intervention: Drug
- RFP Year: 2017
- Status:
- Project: Target determination and exploratory research for discovery of new drugs against Chagas disease.
- Partner: High Energy Accelerator Research Organization (KEK),London School of Hygiene and Tropical Medicine(LSHTM),National Institute of Advanced Industrial Science and Technology,Institute of Tropical Medicine (NEKKEN) Nagasaki University
- Awarded Amount: $882,350
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: NTD (Chagas disease / Leishmaniasis)
- Intervention: Drug
- RFP Year: 2017
- Status:
- Project: Chagas disease and Leishmaniasis Screening between DNDi and Daiichi Sankyo Novare
- Partner: Daiichi Sankyo RD Novare Co., Ltd.,Drugs for Neglected Diseases initiative
- Awarded Amount: $119,000
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: NTD (Chagas disease / Leishmaniasis)
- Intervention: Drug
- RFP Year: 2019
- Status:
- Project: Screening project between Mitsubishi Tanabe and DNDi
- Partner: Mitsubishi Tanabe Pharma Corporation,Drugs for Neglected Diseases initiative
- Awarded Amount: $150,000
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: NTD (Chagas disease / Leishmaniasis)
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Hit-To-Lead development for Neglected Tropical Diseases
- Partner: Mitsubishi Tanabe Pharma Corporation,Drugs for Neglected Diseases initiative
- Awarded Amount: $1,170,663
- Development Stage: Discovery
- Current Stage: Drug Lead Identification
- Disease: NTD (Soil-transmitted helminthiasis)
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Cry5B optimization for Trichuris - whipworm
- Partner: Kao Corporation,University of Massachusetts Medical School,PATH
- Awarded Amount: $923,020
- Development Stage: Discovery
- Current Stage: Drug Target Identification
- Disease: NTD (Chagas disease)
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Target validation and AI-guided identification of Trypanosoma cruzi phosphodiesterase inhibitors for the treatment of Chagas disease
- Partner: Eisai Co., Ltd.,Universidad Nacional de La Plata (UNLP)
- Awarded Amount: $710,077
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: NTD (Leishmaniasis)
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Screening Program
- Partner: University of Tokyo,Drugs for Neglected Diseases initiative
- Awarded Amount: $168,759
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: NTD (Chagas disease / Leishmaniasis)
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Screening Program
- Partner: Daiichi Sankyo RD Novare Co., Ltd.,Drugs for Neglected Diseases initiative
- Awarded Amount: $80,000
- Development Stage: Discovery
- Current Stage: Drug Target Identification
- Disease: NTD (Chagas disease)
- Intervention: Drug
- RFP Year: 2021
- Status:
- Project: Autophagy as a novel drug-development target for Chagas disease
- Partner: National Institute of Advanced Industrial Science and Technology,Drugs for Neglected Diseases initiative
- Awarded Amount: $989,200
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: NTD (Chagas disease)
- Intervention: Drug
- RFP Year: 2021
- Status:
- Project: Screening project between Daiichi Sankyo Company Limited and DNDi
- Partner: Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative
- Awarded Amount: $109,763
- Development Stage: Discovery
- Current Stage: Drug Hit Identification
- Disease: NTD (Chagas disease)
- Intervention: Drug
- RFP Year: 2021
- Status:
- Project: Screening project between Takeda Pharmaceutical Company Ltd. and DNDi
- Partner: Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
- Awarded Amount: $89,946
- Development Stage: Discovery
- Current Stage: Diagnostic Development Feasibility
- Disease: NTD (Schistosomiasis)
- Intervention: Diagnostic
- RFP Year: 2014
- Status:
- Project: Development of a sensitive and specific point-of-care diagnostics for Asian zoonotic schistosomiasis
- Partner: Graduate School of Agricultural and Life Sciences, The University of Tokyo,InBios International, Inc.,University of the Philippines,National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine
- Awarded Amount: $779,036
- Development Stage: Discovery
- Current Stage: Diagnostic Concept Development
- Disease: NTD (Schistosomiasis)
- Intervention: Diagnostic
- RFP Year: 2017
- Status:
- Project: Novel diagnostics for schistosomiasis control: development of defined antigens for detection of Schistosoma infection-specific antibodies in blood and urine
- Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Leiden University Medical Center,Lygature
- Awarded Amount: $763,890
- Development Stage: Discovery
- Current Stage: Diagnostic Concept Development
- Disease: NTD (Mycetoma)
- Intervention: Diagnostic
- RFP Year: 2019
- Status:
- Project: MycEXomics aims to develop a field-friendly point-of-care diagnostic test for mycetoma
- Partner: RIKEN,Hospital General de Mexico,Mycetoma Research Centre (MRC), University of Khartoum,Erasmus University Medical Center
- Awarded Amount: $285,937
- Development Stage: Discovery
- Current Stage: Diagnostic Concept Development
- Disease: NTD (Buruli ulcer)
- Intervention: Diagnostic
- RFP Year: 2020
- Status:
- Project: Development of ‘all-in-one’ diagnostic kit for Buruli ulcer using lateral flow DNA-chromatography
- Partner: Fasmac Co., Ltd.,Hope Commission International,Institut Pasteur de Côte d'Ivoire,Keio University School of Medicine,Nagasaki University,Raoul Follereau Institute Côte d’Ivoire,TBA Co., Ltd.,Teikyo University
- Awarded Amount: $895,584
- Development Stage: Preclinical
- Current Stage: Drug Preclinical development
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Development of ELQ300 as a long acting antimalarial
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
- Awarded Amount: $560,000
- Development Stage: Preclinical
- Current Stage: Drug Preclinical development
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2014
- Status:
- Project: Preclinical and clinical development of (+)-SJ000557733, a novel inhibitor of Plasmodium ATP4
- Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),St. Jude Children’s Research Hospital
- Awarded Amount: $3,768,922
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2014
- Status:
- Project: Lead optimization of a novel mechanism-of-action antimalarial
- Partner: Eisai Co., Ltd.,Broad Institute
- Awarded Amount: $2,997,525
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: E209 a tetraoxane based rapidly acting antimalarial – candidate selection
- Partner: Eisai Co., Ltd.,University of Liverpool,Liverpool School of Tropical Medicine
- Awarded Amount: $207,753
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: Development of a novel mechanism-of-action antimalarial drug with multistage activity
- Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),Broad Institute
- Awarded Amount: $1,999,993
- Development Stage: Preclinical
- Current Stage: Drug Preclinical development
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: DSM421 Clinical Development up to phase IIa GO
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
- Awarded Amount: $7,499,822
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: Identification of pre-clinical candidate as an anti-malarial agent
- Partner: Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $1,761,309
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2017
- Status:
- Project: Lead optimization of potent Gwt1p inhibitors toward a new antimalarial drug with a novel mechanism of action
- Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $2,639,670
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2018
- Status:
- Project: Preclinical development of a new class of Plasmodium DHODH inhibitor for the treatment of malaria
- Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),Broad Institute
- Awarded Amount: $4,214,187
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2018
- Status:
- Project: Mitsubishi Tanabe Lead Optimization of Anti-Malarials
- Partner: Mitsubishi Tanabe Pharma Corporation,Medicines for Malaria Venture (MMV)
- Awarded Amount: $1,922,475
- Development Stage: Preclinical
- Current Stage: Drug Preclinical development
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2018
- Status:
- Project: Preclinical development of a novel mechanism-of-action antimalarial drug with multistage activity
- Partner: Eisai Co., Ltd.,Broad Institute
- Awarded Amount: $5,368,224
- Development Stage: Preclinical
- Current Stage: Drug Preclinical development
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2019
- Status:
- Project: Preclinical studies of potent Gwt1p inhibitor toward IND for antimalarial agent with novel mechanism of action
- Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
- Awarded Amount: $6,828,394
- Development Stage: Preclinical
- Current Stage: Drug Preclinical development
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2019
- Status:
- Project: Preclinical and Clinical Development of SJ733, a Novel PfATP4 Inhibitor for the Treatment of Severe Malaria
- Partner: Eisai Co., Ltd.,University of Kentucky
- Awarded Amount: $5,590,091
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Structured-based approach to develop a novel mechanism-of-action antimalarial with multistage activity
- Partner: Eisai Co., Ltd.,International Centre for Genetic Engineering and Biotechnology ,The Scripps Research Institute,Broad Institute
- Awarded Amount: $4,127,236
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Optimisation of multistage inhibitors of Plasmodium falciparum lysyl t-RNA synthetase for the treatment of malaria
- Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),University of Dundee
- Awarded Amount: $3,538,738
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2021
- Status:
- Project: Preclinical development of a monoclonal antibody to prevent P. falciparum malaria
- Partner: Ehime University,Eisai Co., Ltd.,GlaxoSmithKline plc.,PATH
- Awarded Amount: $5,386,616
- Development Stage: Preclinical
- Current Stage: Vaccine Lead Optimization
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2015
- Status:
- Project: Lead optimization of an evolution-proof malaria transmission-blocking vaccine immunogen that is based on a mosquito protein target and effective against both P.falciparum and P. vivax
- Partner: CellFree Sciences Co. Ltd.,Infectious Disease Research Institute,The University of Florida
- Awarded Amount: $419,285
- Development Stage: Preclinical
- Current Stage: Vaccine Preclinical Development
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2017
- Status:
- Project: Process Development and Clinical Manufacturing of an Immuno-focused, Mosquito-based Pan-malaria transmission-blocking vaccine: AnAPN1 v. 2.0
- Partner: CellFree Sciences Co. Ltd.,Centre Pasteur du Cameroun (CPC),Hamamatsu Pharma Research,Infectious Disease Research Institute,Ology Bioservices Inc.,The University of Florida
- Awarded Amount: $3,484,217
- Development Stage: Preclinical
- Current Stage: Vaccine Lead Optimization
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2018
- Status:
- Project: Further development of a new asexual blood-stage malaria vaccine candidate
- Partner: Ehime University,iBET,European Vaccine Initiative (EVI)
- Awarded Amount: $930,571
- Development Stage: Preclinical
- Current Stage: Vaccine Preclinical Development
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2019
- Status:
- Project: Preclinical development of malaria transmission-blocking vaccine candidate Pfs230D1+ formulated with SA-1 adjuvant
- Partner: Ehime University,Sumitomo Dainippon Pharma Co., Ltd.,PATH
- Awarded Amount: $5,007,283
- Development Stage: Preclinical
- Current Stage: Vaccine Preclinical Development
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2020
- Status:
- Project: First-In-Human Trial of the Pan-Malaria Transmission-Blocking Vaccine AnAPN1
- Partner: Ajinomoto Bio-Pharma Services, GeneDesign (GeneDesign),CellFree Sciences Co. Ltd.,Centre de Recherches Médicales de Lambaréné (CERMEL) ,University of Tübingen (UKT) ,The University of Florida
- Awarded Amount: $6,486,223
- Development Stage: Preclinical
- Current Stage: Vaccine Preclinical Development
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2021
- Status:
- Project: Clinical development of placental malaria vaccine candidates
- Partner: Ehime University,Groupe de Recherche Action en Santé (GRAS),Institut de recherche pour le développement,Institut national de la santé et de la recherche médicale,Noguchi Memorial Institute for Medical Research,University of Copenhagen (UCPH) ,European Vaccine Initiative (EVI)
- Awarded Amount: $4,692,924
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: Tuberculosis
- Intervention: Drug
- RFP Year: 2017
- Status:
- Project: Lead optimization of novel azetidine-based tryptophan synthase inhibitors as new mechanism of action treatment of tuberculosis
- Partner: Eisai Co., Ltd.,Colorado State University,The Global Alliance for TB Drug Development,The University of Chicago,Broad Institute
- Awarded Amount: $2,003,324
- Development Stage: Preclinical
- Current Stage: Vaccine Lead Optimization
- Disease: Tuberculosis
- Intervention: Vaccine
- RFP Year: 2013
- Status:
- Project: Development of rhPIV2 as a Potential New TB Vaccine Candidate
- Partner: National Institutes of Biomedical Innovation, Health and Nutrition,Aeras
- Awarded Amount: $5,649,620
- Development Stage: Preclinical
- Current Stage: Vaccine Lead Optimization
- Disease: Tuberculosis
- Intervention: Vaccine
- RFP Year: 2013
- Status:
- Project: Development of recombinant hPIV2 virus vector as a new TB vaccine
- Partner: National Institutes of Biomedical Innovation, Health and Nutrition,Aeras
- Awarded Amount: $700,000
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: NTD (Lymphatic filariasis / Onchocerciasis)
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Anti-Wolbachia targeted macrofilaricidal drug discovery-lead optimization of lead series chemotypes to deliver novel pre-clinical candidates
- Partner: Eisai Co., Ltd.,University of Liverpool,Liverpool School of Tropical Medicine
- Awarded Amount: $1,093,166
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: NTD (Leishmaniasis)
- Intervention: Drug
- RFP Year: 2014
- Status:
- Project: Lead optimization of the aminopyrazole series for visceral leishmaniasis
- Partner: Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
- Awarded Amount: $4,022,552
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: NTD (Soil-transmitted helminthiasis)
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Cry5B consortium for soil-transmitted helminths
- Partner: Meiji Seika Pharma Co., Ltd.,University of Massachusetts Medical School,PATH
- Awarded Amount: $1,002,996
- Development Stage: Preclinical
- Current Stage: Drug Preclinical development
- Disease: NTD (Leishmaniasis)
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Preclinical efficacy of CpG D35 combination therapy for treatment of complicated cutaneous leishmaniasis
- Partner: GeneDesign, Inc,Drugs for Neglected Diseases initiative
- Awarded Amount: $687,715
- Development Stage: Preclinical
- Current Stage: Drug Preclinical development
- Disease: NTD (Dengue)
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes
- Partner: Chugai Pharmaceutical Co., Ltd.,A∗STAR′s Singapore Immunology Network (SIgN)
- Awarded Amount: $5,348,894
- Development Stage: Preclinical
- Current Stage: Drug Preclinical development
- Disease: NTD (Leishmaniasis)
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: Preclinical development of CpG D35 for combined treatment of cutaneous leishmaniasis
- Partner: GeneDesign, Inc,Drugs for Neglected Diseases initiative
- Awarded Amount: $4,918,672
- Development Stage: Preclinical
- Current Stage: Drug Preclinical development
- Disease: NTD (Leishmaniasis)
- Intervention: Drug
- RFP Year: 2017
- Status:
- Project: Preclinical development and phase I activities on a selected aminopyrazole compound for visceral leishmaniasis
- Partner: Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
- Awarded Amount: $6,047,757
- Development Stage: Preclinical
- Current Stage: Drug Preclinical development
- Disease: NTD (Dengue)
- Intervention: Drug
- RFP Year: 2018
- Status:
- Project: Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes
- Partner: Chugai Pharmaceutical Co., Ltd.,A∗STAR′s Singapore Immunology Network (SIgN)
- Awarded Amount: $4,892,737
- Development Stage: Preclinical
- Current Stage: Drug Preclinical development
- Disease: NTD (Lymphatic filariasis / Onchocerciasis)
- Intervention: Drug
- RFP Year: 2019
- Status:
- Project: Development of AWZ1066S, A Small Molecule anti-Wolbachia Candidate Macrofilaricide Drug
- Partner: Eisai Co., Ltd.,University of Liverpool,Liverpool School of Tropical Medicine
- Awarded Amount: $4,335,812
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: NTD (Chagas disease)
- Intervention: Drug
- RFP Year: 2019
- Status:
- Project: Lead optimization of a candidate series active against Chagas Disease
- Partner: Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative
- Awarded Amount: $4,318,565
- Development Stage: Preclinical
- Current Stage: Drug Preclinical development
- Disease: NTD (Leishmaniasis)
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Preclinical development of DNDI-6174, a drug candidate for leishmaniasis
- Partner: Eisai Co., Ltd.,Drugs for Neglected Diseases initiative
- Awarded Amount: $6,122,938
- Development Stage: Preclinical
- Current Stage: Drug Lead Optimization
- Disease: NTD (Leishmaniasis)
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Lead optimization and preclinical candidate selection from the NTD Drug Discovery Booster series S07 for visceral leishmaniasis
- Partner: Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
- Awarded Amount: $2,257,442
- Development Stage: Preclinical
- Current Stage: Vaccine Preclinical Development
- Disease: NTD (Dengue)
- Intervention: Vaccine
- RFP Year: 2014
- Status:
- Project: Development of a Live Attenuated Tetravalent Dengue Vaccine
- Partner: The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN),Mahidol University
- Awarded Amount: $3,450,276
- Development Stage: Preclinical
- Current Stage: Vaccine Preclinical Development
- Disease: NTD (Chagas disease)
- Intervention: Vaccine
- RFP Year: 2014
- Status:
- Project: Adjuvant Technologies to Advance Chagas Disease Vaccine Development
- Partner: Eisai Co., Ltd.,Baylor College of Medicine (BCM),Aeras,Sabin Vaccine Institute
- Awarded Amount: $2,000,000
- Development Stage: Preclinical
- Current Stage: Vaccine Lead Optimization
- Disease: NTD (Leishmaniasis)
- Intervention: Vaccine
- RFP Year: 2015
- Status:
- Project: Live attenuated prophylactic vaccine for leishmaniasis
- Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,McGill University ,The Ohio State University
- Awarded Amount: $1,832,967
- Development Stage: Preclinical
- Current Stage: Vaccine Preclinical Development
- Disease: NTD (Dengue)
- Intervention: Vaccine
- RFP Year: 2015
- Status:
- Project: Preclinical development of MVDVax, a new dengue vaccine
- Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Institut Pasteur,European Vaccine Initiative (EVI)
- Awarded Amount: $612,902
- Development Stage: Preclinical
- Current Stage: Vaccine Preclinical Development
- Disease: NTD (Leishmaniasis)
- Intervention: Vaccine
- RFP Year: 2016
- Status:
- Project: Preclinical and preparation of early clinical testing of a new vaccine candidate against cutaneous leishmaniasis
- Partner: Nagasaki University,London School of Hygiene and Tropical Medicine(LSHTM),Mologen ,Charité –Universitätsmedizin Berlin,European Vaccine Initiative (EVI)
- Awarded Amount: $4,096,664
- Development Stage: Preclinical
- Current Stage: Vaccine Preclinical Development
- Disease: NTD (Dengue)
- Intervention: Vaccine
- RFP Year: 2016
- Status:
- Project: Development of novel dengue virus-like particle (VLP) vaccines against all four serotypes
- Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,National Institute of Infectious Diseases,VLP Therapeutics
- Awarded Amount: $986,540
- Development Stage: Preclinical
- Current Stage: Vaccine Preclinical Development
- Disease: NTD (Dengue)
- Intervention: Vaccine
- RFP Year: 2018
- Status:
- Project: The development and production of cGMP lots of a novel tetravalent dengue virus-like particle (VLP) vaccine
- Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Johns Hopkins University,Latham BioPharm Group,National Institute of Infectious Diseases,VLP Therapeutics
- Awarded Amount: $4,422,091
- Development Stage: Preclinical
- Current Stage: Vaccine Lead Optimization
- Disease: NTD (Leishmaniasis)
- Intervention: Vaccine
- RFP Year: 2018
- Status:
- Project: Live attenuated prophylactic vaccine for leishmaniasis
- Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Gennova Biopharmaceuticals Ltd.,McGill University ,The Ohio State University
- Awarded Amount: $3,998,989
- Development Stage: Preclinical
- Current Stage: Vaccine Preclinical Development
- Disease: NTD (Leishmaniasis)
- Intervention: Vaccine
- RFP Year: 2018
- Status:
- Project: Immune therapy to prevent VL complications
- Partner: University of Tokyo,International Center for Diarrheal Disease Research Bangladesh,Infectious Disease Research Institute
- Awarded Amount: $558,315
- Development Stage: Preclinical
- Current Stage: Vaccine Lead Optimization
- Disease: NTD (Chagas disease)
- Intervention: Vaccine
- RFP Year: 2019
- Status:
- Project: Optimization and pre-clinical development of a Trypanosoma cruzi Cyp19 knock-out strain as a live vaccine for Chagas disease.
- Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Ohio University,The Ohio State University
- Awarded Amount: $1,097,927
- Development Stage: Preclinical
- Current Stage: Diagnostic Product Design
- Disease: NTD (Leishmaniasis)
- Intervention: Diagnostic
- RFP Year: 2019
- Status:
- Project: Production, validation and use of Leishmanin skin test (LST) for detection of Leishmania exposure and immunity
- Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Gennova Biopharmaceuticals Ltd.,McGill University ,U.S. Food and Drug Administration,The Ohio State University
- Awarded Amount: $2,257,699
- Development Stage: Clinical
- Current Stage: Drug Clinical Phase2
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Development of DSM265 as a long acting antimalarial compound
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
- Awarded Amount: $2,538,796
- Development Stage: Clinical
- Current Stage: Drug Clinical Phase1
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2014
- Status:
- Project: Testing DSM265, a novel antimalarial acting through DHODH, in combination with OZ439
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
- Awarded Amount: $1,290,883
- Development Stage: Clinical
- Current Stage: Drug Clinical Phase2
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2015
- Status:
- Project: Commercial formulation development of DSM265
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
- Awarded Amount: $1,905,341
- Development Stage: Clinical
- Current Stage: Drug Clinical Phase2
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: Phase 2 Trial of SJ733, a Novel PfATP4 Inhibitor for Malaria
- Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV),University of Kentucky
- Awarded Amount: $4,500,001
- Development Stage: Clinical
- Current Stage: Drug Clinical Phase2
- Disease: Malaria
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: Formulation Optimization Work on DSM265
- Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
- Awarded Amount: $1,589,999
- Development Stage: Clinical
- Current Stage: Vaccine Phase1 Clinical Development
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2013
- Status:
- Project: Clinical Development of BK-SE36/CpG Malaria Vaccine
- Partner: Research Institute for Microbial Diseases (RIMD), Osaka University,Gulu University, Uganda
- Awarded Amount: $714,500
- Development Stage: Clinical
- Current Stage: Vaccine Phase1 Clinical Development
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2014
- Status:
- Project: Clinical development of the BK-SE36 malaria vaccine candidate
- Partner: Research Institute for Microbial Diseases (RIMD), Osaka University,Centre National de Recherche et de Formation sur le Paludisme (CNRFP),European Vaccine Initiative (EVI)
- Awarded Amount: $999,999
- Development Stage: Clinical
- Current Stage: Vaccine Phase1 Clinical Development
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2016
- Status:
- Project: Clinical Development of BK-SE36/CpG Malaria Vaccine: safety evaluation of BK-SE36/CpG in the malaria endemic population
- Partner: Medical Center for Translational Research (MTR), Osaka University Hospital,Institut de Recherche en Sciences de la Santé (IRSS),Nobelpharma Co., Ltd.,Research Institute for Microbial Diseases (RIMD), Osaka University,European Vaccine Initiative (EVI)
- Awarded Amount: $2,781,588
- Development Stage: Clinical
- Current Stage: Vaccine Phase1 Clinical Development
- Disease: Malaria
- Intervention: Vaccine
- RFP Year: 2019
- Status:
- Project: Preparatory phase II for the malaria vaccine candidate NPC-SE36/CpG
- Partner: Nobelpharma Co., Ltd.,Groupe de Recherche Action en Santé (GRAS),Research Institute for Microbial Diseases (RIMD), Osaka University,European Vaccine Initiative (EVI)
- Awarded Amount: $1,870,777
- Development Stage: Clinical
- Current Stage: Diagnostic Product Validation
- Disease: Malaria
- Intervention: Diagnostic
- RFP Year: 2015
- Status:
- Project: Development of a fully automated malaria diagnostic system and field evaluation for practical use
- Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Juntendo University,Kenya Medical Research Institute (KEMRI-CGHR),Malaria No More Japan (MNMJ),National Institute of Advanced Industrial Science and Technology,Panasonic Corporation
- Awarded Amount: $964,500
- Development Stage: Clinical
- Current Stage: Diagnostic Product Development
- Disease: Malaria
- Intervention: Diagnostic
- RFP Year: 2019
- Status:
- Project: Commercial Development of a Saliva-based Malaria Asymptomatic and Asexual Rapid Test (SMAART-1)
- Partner: CellFree Sciences Co. Ltd.,ERADA Technology Alliance, Ltd.,Frontier Institute Co., Ltd.,Oasis Diagnostics Corp.,The University of Florida
- Awarded Amount: $1,382,696
- Development Stage: Clinical
- Current Stage: Vaccine Phase2 Clinical Development
- Disease: Tuberculosis
- Intervention: Vaccine
- RFP Year: 2015
- Status:
- Project: DAR-901 whole cell booster vaccine to prevent TB infection in adolescents (“DAR-PIA”)
- Partner: Tokyo Medical and Dental University,Muhimbili University of Health and Allied Sciences (MUHAS),Geisel School of Medicine at Dartmouth
- Awarded Amount: $1,423,590
- Development Stage: Clinical
- Current Stage: Diagnostic Product Validation
- Disease: Tuberculosis
- Intervention: Diagnostic
- RFP Year: 2015
- Status:
- Project: Highly Sensitive POC TB-LAM Rapid Diagnostic Test
- Partner: Fujifilm Corporation ,Foundation for Innovative New Diagnostics (FIND)
- Awarded Amount: $2,160,577
- Development Stage: Clinical
- Current Stage: Diagnostic Product Validation
- Disease: Tuberculosis
- Intervention: Diagnostic
- RFP Year: 2017
- Status:
- Project: Fujifilm SILVAMP TB LAM – A Sensitive point-of-care Tuberculosis Test
- Partner: Fujifilm Corporation ,Foundation for Innovative New Diagnostics (FIND)
- Awarded Amount: $4,217,169
- Development Stage: Clinical
- Current Stage: Diagnostic Product Validation
- Disease: Tuberculosis
- Intervention: Diagnostic
- RFP Year: 2020
- Status:
- Project: Product Development of LFA platform for improving sensitivity of Point-of-Care assays for infectious disease with main focus on Tuberculosis
- Partner: Asahi Kasei Corporation,Biopromic AB
- Awarded Amount: $2,266,257
- Development Stage: Clinical
- Current Stage: Diagnostic Product Development
- Disease: Tuberculosis
- Intervention: Diagnostic
- RFP Year: 2021
- Status:
- Project: Viability & Value of the Lung Flute ECO for Sputum Sample Collection and Tuberculosis Testing in Vulnerable Groups (3V Trial)
- Partner: Acoustic Innovations (AI),Center for Health Promotion and Research (CHPR),Institute of Tropical Medicine (ITM),Research Institute of Tuberculosis
- Awarded Amount: $833,738
- Development Stage: Clinical
- Current Stage: Drug Clinical Phase2
- Disease: NTD (Chagas disease)
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: A new treatment for Chagas disease
- Partner: Eisai Co., Ltd.,Drugs for Neglected Diseases initiative
- Awarded Amount: $3,840,892
- Development Stage: Clinical
- Current Stage: Drug Clinical Phase1
- Disease: NTD (Schistosomiasis)
- Intervention: Drug
- RFP Year: 2013
- Status:
- Project: Development and registration of a new praziquantel pediatric formulation for the treatment of schistosomiasis
- Partner: Astellas Pharma Inc.,Farmanguinhos,Merck KGaA,Simcyp Limited,Swiss Tropical and Public Health Institute,Lygature
- Awarded Amount: $1,864,898
- Development Stage: Clinical
- Current Stage: Drug Clinical Phase2
- Disease: NTD (Schistosomiasis)
- Intervention: Drug
- RFP Year: 2014
- Status:
- Project: Development and registration of a new praziquantel pediatric formulation for the treatment of schistosomiasis
- Partner: Astellas Pharma Inc.,Farmanguinhos,Merck KGaA,Simcyp Limited,Swiss Tropical and Public Health Institute,Lygature
- Awarded Amount: $4,856,513
- Development Stage: Clinical
- Current Stage: Drug Clinical Phase3
- Disease: NTD (Schistosomiasis)
- Intervention: Drug
- RFP Year: 2016
- Status:
- Project: Development and registration of a new pediatric praziquantel formulation for the treatment of schistosomiasis in preschool-aged children
- Partner: Astellas Pharma Inc.,Farmanguinhos,Merck KGaA,Schistosomiasis Control Initiative (SCI),Simcyp Limited,Swiss Tropical and Public Health Institute,Lygature
- Awarded Amount: $4,679,698
- Development Stage: Clinical
- Current Stage: Drug Clinical Phase2
- Disease: NTD (Mycetoma)
- Intervention: Drug
- RFP Year: 2017
- Status:
- Project: Mycetoma Treatment, Fosravuconazole Clinical Trial
- Partner: Eisai Co., Ltd.,Drugs for Neglected Diseases initiative
- Awarded Amount: $2,526,217
- Development Stage: Clinical
- Current Stage: Drug Registration
- Disease: NTD (Schistosomiasis)
- Intervention: Drug
- RFP Year: 2018
- Status:
- Project: Treating schistosomiasis in preschool-aged children: development, registration and access to L-praziquantel orally disintegrating tablet formulation
- Partner: Astellas Pharma Inc.,Farmanguinhos,Kenya Medical Research Institute (KEMRI-CGHR),Merck KGaA,Schistosomiasis Control Initiative (SCI),Swiss Tropical and Public Health Institute,Université Félix Houphouët Boigny (UFHB),Lygature
- Awarded Amount: $4,523,295
- Development Stage: Clinical
- Current Stage: Drug Clinical Phase1
- Disease: NTD (Leishmaniasis)
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Clinical development of CpG-D35 for combined treatment of cutaneous leishmaniasis
- Partner: Ajinomoto Bio-Pharma Services, GeneDesign (GeneDesign),University of Tokyo,Drugs for Neglected Diseases initiative
- Awarded Amount: $6,923,997
- Development Stage: Clinical
- Current Stage: Drug Registration
- Disease: NTD (Schistosomiasis)
- Intervention: Drug
- RFP Year: 2020
- Status:
- Project: Adoption of Levo-Praziquantel 150mg for schistosomiasis by endemic countries
- Partner: Astellas Pharma Inc.,Kenya Medical Research Institute (KEMRI-CGHR),Klinikum rechts der Isar der Technischen Universität München, Department of Neurology (MRI),Merck KGaA,SCI Foundation,Swiss Tropical and Public Health Institute,Université Félix Houphouët Boigny (UFHB),Lygature
- Awarded Amount: $2,622,542
- Development Stage: Clinical
- Current Stage: Drug Clinical Phase2
- Disease: NTD (Lymphatic filariasis / Onchocerciasis)
- Intervention: Drug
- RFP Year: 2022
- Status:
- Project: Phase II Clinical Development of AWZ1066S, a Small Molecule anti-Wolbachia Candidate Macrofilaricide Drug
- Partner: Eisai Co., Ltd.,University Hospital of Bonn (UKB),University of Buea (UoB) ,University of Liverpool,Liverpool School of Tropical Medicine
- Awarded Amount: $7,960,044
- Development Stage: Clinical
- Current Stage: Diagnostic Product Development
- Disease: NTD (Schistosomiasis)
- Intervention: Diagnostic
- RFP Year: 2020
- Status:
- Project: A schistosomiasis rapid diagnostic test to support control programmes in monitoring treatment impact and reassessment mapping
- Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Leiden University Medical Center,Merck KGaA,Foundation for Innovative New Diagnostics (FIND)
- Awarded Amount: $3,733,973
- Development Stage: Clinical
- Current Stage: Diagnostic Product Development
- Disease: NTD (Buruli ulcer)
- Intervention: Diagnostic
- RFP Year: 2020
- Status:
- Project: A Buruli ulcer mycolactone (BU-MYCOLAC) rapid diagnostic test to enhance early diagnosis and treatment
- Partner: Nagasaki University,Drugs and Diagnostics for Tropical Diseases,Swiss Tropical and Public Health Institute,Foundation for Innovative New Diagnostics (FIND)
- Awarded Amount: $1,836,107
- Development Stage: Clinical
- Current Stage: Diagnostic Product Validation
- Disease: NTD (Chagas disease)
- Intervention: Diagnostic
- RFP Year: 2020
- Status:
- Project: Field validation of Trypanosoma cruzi-LAMP: a molecular point-of-care test for the control of congenital Chagas disease
- Partner: Eiken Chemical Co., Ltd.,Centro para el Desarrollo de Investigación Científica (CEDIC) ,Ciencia y Estudios Aplicados Para el Desarrollo en Salud y Medio Ambiente (CEADES) ,AI Biosciences Inc. ,Fundacion Mundo Sano,Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (CONICET-INGEBI),Nagasaki University,Barcelona Institute for Global Health (ISGLOBAL)
- Awarded Amount: $1,471,273